Pediatric Emergencies — Part 4: Neurologic, Metabolic & Fluid Emergencies
Febrile seizure evaluation, status epilepticus protocol with stepwise treatment, clinical dehydration assessment, WHO dehydration classification, ORT protocol, IV fluid calculation with Holliday-Segar rule, hyponatremia correction, and pediatric diabetic ketoacidosis management including 2-bag system and cerebral edema monitoring.
1. Febrile Seizures
Febrile seizures are the most common seizure type in childhood, affecting 2-5% of children between 6 months and 5 years of age. They are defined as seizures occurring in the setting of fever (temperature ≥38°C / 100.4°F) in a child aged 6 months to 5 years, without evidence of central nervous system infection, metabolic disturbance, or a history of afebrile seizures. Despite their frightening presentation, febrile seizures are generally benign with an excellent prognosis.1 2
1.1 Simple vs Complex Febrile Seizures
| Feature | Simple Febrile Seizure | Complex Febrile Seizure |
|---|---|---|
| Duration | <15 minutes | ≥15 minutes |
| Type | Generalized (tonic-clonic) | Focal features (lateralizing movements, asymmetric posturing) |
| Occurrence | Single seizure in 24-hour period | Multiple seizures within 24 hours |
| Post-ictal period | Brief (returns to baseline within 1 hour) | Prolonged or incomplete recovery |
| Frequency | ~70-75% of all febrile seizures | ~25-30% of all febrile seizures |
| Recurrence risk | ~30% (1 recurrence); ~10% (≥3 recurrences) | ~50% recurrence |
| Epilepsy risk | 1-2% (similar to general population) | 4-6% |
1.2 Evaluation of Simple Febrile Seizures
The following workup is specifically guided by clinical practice guidelines for simple febrile seizures.1
| Investigation | Recommendation | Rationale |
|---|---|---|
| Lumbar puncture | Not routinely recommended if the child is well-appearing and fully recovered; consider in infants 6-12 months who are unvaccinated or incompletely vaccinated against Hib and S. pneumoniae; strongly consider if the child received antibiotics (may mask meningitis signs) | Risk of bacterial meningitis is very low in a child who has returned to baseline neurologic function |
| Electroencephalography (EEG) | NOT recommended after a simple febrile seizure | Does not predict recurrence or subsequent epilepsy; may show nonspecific abnormalities that lead to unnecessary treatment |
| Neuroimaging (CT/MRI) | NOT recommended after a simple febrile seizure | Yield is extremely low in simple febrile seizures; CT exposes the child to ionizing radiation without benefit |
| Blood tests | NOT routinely recommended | Electrolytes, glucose, CBC are guided by clinical assessment, not by the seizure itself; may obtain directed labs to evaluate the source of fever |
| Identify fever source | Yes — evaluate and treat the source of fever | The seizure is triggered by the fever; identify and manage the underlying febrile illness |
1.3 Parent/Caregiver Education
| Topic | Key Messages |
|---|---|
| Prognosis | Simple febrile seizures do not cause brain damage, intellectual disability, or death; they are not epilepsy |
| Recurrence | ~30% chance of another febrile seizure, highest in the first year after initial episode; risk factors for recurrence include younger age at onset, lower temperature at time of seizure, shorter duration of fever before seizure, family history of febrile seizures |
| What to do during a seizure | Place child on side (recovery position); clear area of hard/sharp objects; do NOT put anything in the mouth; do NOT restrain; time the seizure; call emergency services if seizure lasts >5 minutes |
| Antipyretic prophylaxis | Antipyretics (acetaminophen, ibuprofen) treat discomfort from fever but do NOT prevent febrile seizures; routine prophylactic use is not recommended for seizure prevention |
| Anticonvulsant prophylaxis | NOT recommended for simple febrile seizures; potential side effects of daily anticonvulsant medications outweigh the risks of recurrence |
1.4 Management of Complex Febrile Seizures
Complex febrile seizures warrant more thorough evaluation:
- Lumbar puncture: lower threshold, especially if prolonged postictal state, focal features, or age <12 months
- Neuroimaging: consider emergent CT if focal seizure, prolonged postictal deficit (Todd paralysis >1 hour), or concern for structural lesion
- EEG: consider outpatient EEG if focal features or multiple complex febrile seizures
- Observation: longer period of observation in ED or hospital admission
- Neurology referral: recommended for recurrent complex febrile seizures
2. Status Epilepticus
Status epilepticus (SE) is defined as a seizure lasting ≥5 minutes or two or more seizures without return to baseline neurologic function between seizures. This represents a time-sensitive neurologic emergency. Mortality is 3-7% in children, and morbidity (including cognitive sequelae) increases with seizure duration. The likelihood of spontaneous termination decreases with each passing minute, making rapid, protocolized benzodiazepine administration the single most important intervention.3 4
2.1 Status Epilepticus Protocol: Stepwise Treatment
Phase 1: Stabilization and First-Line Therapy (0-5 minutes)
| Time | Action |
|---|---|
| 0–2 min | ABCs: position airway, suction if needed, supplemental oxygen, pulse oximetry, place on monitor; check glucose (treat hypoglycemia immediately: D10W 5 mL/kg IV for neonates, D25W 2-4 mL/kg for infants) |
| 0–5 min | BENZODIAZEPINE (first-line) — administer one of the following: |
| Drug | Route | Dose | Max Dose | Notes |
|---|---|---|---|---|
| Midazolam | IM | 0.2 mg/kg | 10 mg | Preferred if no IV access (fastest to administer) |
| Midazolam | IN (intranasal) | 0.2 mg/kg | 10 mg | Use concentrated formulation (5 mg/mL); split between nares |
| Midazolam | Buccal | 0.2 mg/kg | 10 mg | Place between cheek and gum |
| Midazolam | IV | 0.1-0.2 mg/kg | 10 mg | If IV access already established |
| Lorazepam | IV | 0.1 mg/kg | 4 mg | Longer anticonvulsant duration (~12-24 hours) than midazolam |
| Diazepam | IV | 0.2 mg/kg | 10 mg (child); 20 mg (adolescent) | Rapid onset but short anticonvulsant duration (~20 min); redistribution |
| Diazepam | PR (rectal) | 0.5 mg/kg | 20 mg | For home/prehospital use; gel formulation available |
Phase 2: Established Status Epilepticus (5-20 minutes)
| Time | Action |
|---|---|
| 5–10 min | If seizure continues: give second dose of benzodiazepine (same drug and route, or alternative route/drug if first was not IV and IV is now available) |
| 5–20 min | Establish IV/IO access if not already obtained |
| 5–20 min | Order labs: BMP (glucose, sodium, calcium, magnesium), CBC, VBG, lactate, anticonvulsant levels (if applicable), toxicology screen |
| 10–20 min | If seizure persists after 2 doses of benzodiazepine: proceed to second-line therapy |
Phase 3: Second-Line Therapy (20-40 minutes)
Choose ONE of the following. The ESETT trial in 2019 demonstrated non-inferiority among these three agents for benzodiazepine-refractory status epilepticus.4
| Drug | Dose | Administration | Pros | Cons |
|---|---|---|---|---|
| Levetiracetam | 40-60 mg/kg IV (max 4,500 mg) | Over 10-15 minutes | Minimal sedation; no cardiovascular depression; no drug interactions; safe in hepatic dysfunction | May be slightly less effective than fosphenytoin in some subgroups; IV formulation required |
| Fosphenytoin | 20 mg PE/kg IV (max 1,500 mg PE) | Over 10-20 minutes (max rate: 3 mg PE/kg/min in children, 150 mg PE/min in adults) | Long track record; effective | Hypotension, arrhythmia (requires cardiac monitoring); contraindicated in known cardiac conduction defects; drug interactions |
| Phenobarbital | 20 mg/kg IV (max 1,000 mg) | Over 15-20 minutes (max rate: 1 mg/kg/min) | Effective especially in neonates; long duration of action | Significant respiratory depression and sedation; hypotension; may obscure neurologic exam |
| Valproic acid | 20-40 mg/kg IV (max 3,000 mg) | Over 5-10 minutes | Broad spectrum; minimal hemodynamic effects | Hepatotoxicity (avoid in age <2 years, mitochondrial disease); pancreatitis; teratogenic |
Phase 4: Refractory Status Epilepticus (>40 minutes)
If seizures persist despite adequate doses of benzodiazepine AND one second-line agent:
| Intervention | Details |
|---|---|
| Try a second second-line agent | If levetiracetam was used first, try fosphenytoin or phenobarbital (or vice versa) |
| Prepare for RSI and continuous infusion | If seizure continues, intubate for airway protection and begin one of the following: |
| Midazolam infusion | Load: 0.2 mg/kg IV bolus; Infusion: 0.05-2 mg/kg/hr; titrate to burst suppression on continuous EEG |
| Pentobarbital infusion | Load: 5-15 mg/kg IV over 30-60 min; Infusion: 0.5-5 mg/kg/hr; significant hemodynamic depression — requires vasopressor support |
| Propofol infusion | Load: 1-2 mg/kg IV; Infusion: 1-5 mg/kg/hr; CAUTION: propofol infusion syndrome risk in children (metabolic acidosis, rhabdomyolysis, cardiac failure); limit duration and dose; generally avoid in young children |
| Ketamine infusion | Load: 1-2 mg/kg IV; Infusion: 0.5-5 mg/kg/hr; NMDA antagonist; may be neuroprotective; less hemodynamic depression; increasing use in pediatric RSE |
2.2 Key Principles
- Time is brain: every minute of ongoing seizure increases neuronal injury and decreases the probability of seizure termination
- Do not under-dose benzodiazepines: a common error is giving subtherapeutic doses; use full weight-based dosing
- IM midazolam for no IV access: the RAMPART trial demonstrated that IM midazolam was at least as effective as IV lorazepam when IV access was not pre-existing, primarily because of faster time to drug administration
- Monitor for respiratory depression: all anticonvulsants can cause hypoventilation; have bag-mask ventilation equipment immediately available
- Continuous EEG monitoring is essential during treatment of refractory status epilepticus to detect ongoing electrographic seizures after clinical motor manifestations have ceased (electroclinical dissociation)3 4
3. Dehydration Assessment and Fluid Management
Dehydration is the most common fluid and electrolyte disturbance in pediatric emergency medicine, most frequently caused by acute gastroenteritis. Accurate assessment of dehydration severity guides the urgency and route of rehydration. Oral rehydration therapy is the preferred method for mild-moderate dehydration and is underutilized in many emergency departments.5 6
3.1 Clinical Dehydration Scale (CDS)
The Clinical Dehydration Scale is a validated 4-item scoring tool for children 1 month to 5 years with suspected dehydration due to gastroenteritis.5
| Feature | 0 Points | 1 Point | 2 Points |
|---|---|---|---|
| General appearance | Normal | Thirsty, restless, or lethargic but irritable when touched | Drowsy, limp, cold, sweaty; ± comatose |
| Eyes | Normal | Slightly sunken | Very sunken |
| Mucous membranes/tongue | Moist | Sticky | Dry |
| Tears | Present | Decreased | Absent |
| Total Score | Dehydration Severity | Estimated Deficit |
|---|---|---|
| 0 | No dehydration | <3% |
| 1–4 | Some (mild-moderate) dehydration | 3-6% |
| 5–8 | Moderate-severe dehydration | 6-9% |
3.2 WHO Dehydration Classification
The World Health Organization uses a simplified classification system widely applied in resource-limited settings and endorsed for global use.6
| Classification | Clinical Signs | Estimated Deficit | Treatment |
|---|---|---|---|
| No dehydration | No signs of dehydration; child drinks normally; all clinical signs negative | <5% (50 mL/kg) | Plan A: Home management; continue oral fluids and feeding; educate caregiver on danger signs |
| Some dehydration (≥2 of the following signs) | Restless/irritable; sunken eyes; drinks eagerly/thirsty; skin pinch goes back slowly (1-2 seconds) | 5-10% (50-100 mL/kg) | Plan B: ORS 75 mL/kg over 4 hours in supervised setting; reassess after 4 hours |
| Severe dehydration (≥2 of the following signs) | Lethargic/unconscious; sunken eyes; unable to drink or drinks poorly; skin pinch goes back very slowly (>2 seconds) | >10% (>100 mL/kg) | Plan C: IV fluids immediately: 30 mL/kg LR (or NS) in 30 min (infant) or 1 hr (child >1 yr), then 70 mL/kg over 5 hrs (infant) or 2.5 hrs (child); reassess frequently |
3.3 Traditional Clinical Assessment
| Sign | Mild (3-5%) | Moderate (6-9%) | Severe (≥10%) |
|---|---|---|---|
| Mental status | Alert, normal | Irritable, restless | Lethargic, obtunded |
| Thirst | Slightly increased | Moderately increased | Drinks poorly; too lethargic to drink |
| Heart rate | Normal | Mildly increased | Markedly increased |
| Blood pressure | Normal | Normal (compensated) | Hypotension (decompensated) |
| Respiratory rate | Normal | Increased | Deep (Kussmaul if acidotic) |
| Eyes | Normal | Sunken | Deeply sunken |
| Tears | Present | Decreased | Absent |
| Mucous membranes | Moist | Dry | Parched |
| Skin turgor | Normal | Decreased (tenting 1-2 sec) | Markedly decreased (tenting >2 sec) |
| Capillary refill | <2 seconds | 2-3 seconds | >3 seconds |
| Urine output | Normal to slightly decreased | Decreased (oliguria) | Minimal or anuria |
| Fontanelle (if open) | Flat | Sunken | Markedly sunken |
3.4 Oral Rehydration Therapy (ORT) Protocol
ORT is the first-line treatment for mild-to-moderate dehydration and is as effective as IV rehydration for gastroenteritis-related dehydration. It is recommended by the international health and pediatric professional societies as the preferred rehydration method.5 6
| Phase | Volume | Method | Duration |
|---|---|---|---|
| Rehydration phase | 50 mL/kg (mild) or 100 mL/kg (moderate) | ORS solution (e.g., standard WHO-ORS: Na 75 mEq/L, glucose 75 mmol/L, osmolality 245 mOsm/L); give small frequent sips (5-10 mL every 1-2 minutes via syringe, cup, or spoon) | 4 hours |
| Maintenance phase | Replace ongoing losses: 10 mL/kg for each watery stool; 2 mL/kg for each vomit | Continue ORS + resume age-appropriate diet (BRAT diet not specifically recommended; early refeeding encouraged) | Until diarrhea resolves |
ORT Failure (indication for IV fluids):
- Persistent vomiting despite small frequent sips (give ondansetron 0.15 mg/kg IV/PO, max 4 mg, to reduce emesis and improve ORT success)
- Severe dehydration with hemodynamic instability
- Altered mental status
- Ileus / abdominal distension
- Inability to keep pace with ongoing losses
3.5 IV Fluid Calculation: Deficit Replacement + Maintenance
Step 1: Calculate Deficit Volume
Deficit (mL) = estimated % dehydration × body weight (kg) × 10
Example: 10 kg child with 7% dehydration → 0.07 × 10 × 1000 = 700 mL deficit
Step 2: Calculate Maintenance Fluids (Holliday-Segar 4-2-1 Rule)
| Body Weight | Hourly Rate | Daily Rate |
|---|---|---|
| First 10 kg | 4 mL/kg/hr | 100 mL/kg/day |
| Next 10 kg (11–20 kg) | 2 mL/kg/hr | 50 mL/kg/day |
| Each additional kg (>20 kg) | 1 mL/kg/hr | 20 mL/kg/day |
Examples:
| Child Weight | Hourly Maintenance Rate | Daily Maintenance Volume |
|---|---|---|
| 8 kg | 4 × 8 = 32 mL/hr | 100 × 8 = 800 mL/day |
| 15 kg | (4 × 10) + (2 × 5) = 50 mL/hr | 1,000 + 250 = 1,250 mL/day |
| 25 kg | (4 × 10) + (2 × 10) + (1 × 5) = 65 mL/hr | 1,000 + 500 + 100 = 1,600 mL/day |
| 40 kg | (4 × 10) + (2 × 10) + (1 × 20) = 80 mL/hr | 1,000 + 500 + 400 = 1,900 mL/day |
| 70 kg | (4 × 10) + (2 × 10) + (1 × 50) = 110 mL/hr | Maximum typically capped at ~2,400 mL/day |
Step 3: Total Fluid Plan
- Subtract any boluses already given from the deficit volume
- Replace deficit over 24 hours (give half in first 8 hours, remainder over next 16 hours) for isotonic dehydration
- Add maintenance to deficit replacement
- Replace ongoing losses mL for mL
Step 4: Fluid Type
- Maintenance IV fluid: isotonic crystalloid (NS or LR) is now recommended for pediatric maintenance fluids to reduce risk of hospital-acquired hyponatremia; hypotonic fluids (0.45% NS, D5 0.2% NS) are no longer recommended as routine maintenance due to risk of hyponatremia
- Add dextrose: D5NS or D5LR for maintenance once serum glucose is normal
- Add potassium: 20 mEq/L KCl to maintenance fluid once urine output is established and potassium level is confirmed normal or low5 7
4. Hyponatremia
Hyponatremia (serum sodium <135 mEq/L) in children can be life-threatening, particularly when acute or severe, due to the risk of cerebral edema. Conversely, overly rapid correction carries the risk of osmotic demyelination syndrome (ODS), though ODS is less common in children than adults.7
4.1 Classification
| Severity | Serum Na | Symptoms |
|---|---|---|
| Mild | 130-134 mEq/L | Often asymptomatic; may have nausea, headache |
| Moderate | 125-129 mEq/L | Nausea, headache, lethargy, muscle cramps |
| Severe | <125 mEq/L | Altered mental status, seizures, coma, respiratory arrest |
4.2 Symptomatic Hyponatremia Emergency Treatment
| Indication | Treatment | Goal |
|---|---|---|
| Seizures or altered mental status from acute hyponatremia | 3% hypertonic saline (513 mEq/L): 2-5 mL/kg IV over 10-20 minutes; may repeat once if symptoms persist | Raise serum Na by 4-6 mEq/L to stop seizures; this small increase is usually sufficient to resolve acute symptoms |
| After acute symptoms controlled | Slow correction with NS or fluid restriction | Maximum correction rate: 8-10 mEq/L in 24 hours (some guidelines recommend ≤8 mEq/L/24h); faster rates risk osmotic demyelination |
| Chronic hyponatremia (>48 hours or unknown duration) | Even more cautious correction: 6-8 mEq/L in 24 hours | Higher risk of ODS with rapid correction of chronic hyponatremia |
4.3 3% Saline Quick Reference
- Concentration: 513 mEq Na/L
- Expected Na rise: 1 mEq/L per 1 mL/kg of 3% saline administered
- Practical dosing: 2 mL/kg bolus of 3% saline raises Na by approximately 2 mEq/L
- Monitor: serum Na every 1-2 hours during active correction; every 4-6 hours during slower correction
- If overcorrection occurs: consider administering desmopressin (DDAVP) 0.25-1 mcg IV and/or D5W to re-lower sodium
5. Pediatric Diabetic Ketoacidosis (DKA)
DKA is the most common life-threatening endocrine emergency in children. It occurs in approximately 30% of children at initial diabetes diagnosis and 1-10% of known diabetics per year. Cerebral edema is the most feared complication, occurring in 0.5-1% of DKA episodes and accounting for 60-90% of DKA-related deaths in children. Unlike adult DKA protocols, pediatric DKA management emphasizes cautious fluid replacement and avoidance of rapid osmolality shifts.8 9
5.1 DKA Diagnostic Criteria
| Parameter | DKA Criteria |
|---|---|
| Blood glucose | >200 mg/dL (>11 mmol/L); or known diabetes with glucose >250 mg/dL |
| Venous pH | <7.30 |
| Serum bicarbonate | <15 mEq/L |
| Ketonemia/ketonuria | Positive serum beta-hydroxybutyrate (>3 mmol/L) or moderate-large urine ketones |
| Anion gap | Elevated (>12) |
DKA Severity:
| Severity | Venous pH | Bicarbonate | Clinical |
|---|---|---|---|
| Mild | 7.20-7.30 | 10-15 mEq/L | Alert; mild dehydration |
| Moderate | 7.10-7.19 | 5-9 mEq/L | Lethargic; Kussmaul respirations; moderate dehydration |
| Severe | <7.10 | <5 mEq/L | Obtunded/comatose; Kussmaul or respiratory depression; severe dehydration; possible hemodynamic instability |
5.2 Initial Resuscitation
| Priority | Intervention | Details |
|---|---|---|
| 1 | Volume resuscitation | 10 mL/kg NS bolus over 30-60 min (NOT 20 mL/kg); may repeat × 1 if hemodynamically unstable; total initial bolus should not exceed 20 mL/kg |
| 2 | Laboratory studies | BMP (glucose, Na, K, Cl, CO2, BUN, Cr), VBG, beta-hydroxybutyrate, phosphorus, magnesium, calcium, CBC, HbA1c, UA |
| 3 | Correct electrolytes | If K <3.5: add 40 mEq/L KCl to IV fluids and HOLD insulin until K ≥3.5; if K 3.5-5.5: add 20-40 mEq/L potassium to IV fluids; if K >5.5: hold potassium but recheck q1-2h (K will fall with insulin and hydration) |
| 4 | Establish monitoring | Continuous telemetry; hourly vitals; strict I&O; neuro checks q1h; POC glucose q1h |
5.3 Fluid Replacement: 2-Bag System
The 2-bag system allows rapid adjustment of dextrose concentration without interrupting fluid delivery or requiring new bag preparation. This is the preferred method in many pediatric centers.8 9
Principle: Two bags of identical electrolyte composition run simultaneously through a Y-connector; one bag contains dextrose (D10NS + KCl), the other does not (NS + KCl). The relative rates of the two bags are adjusted to achieve the desired dextrose concentration.
Step 1: Calculate total fluid rate
- Estimated dehydration: assume 5-7% for moderate DKA, 7-10% for severe
- Deficit = % dehydration × weight (kg) × 1,000 (mL)
- Subtract any bolus already given from the deficit
- Replace remaining deficit evenly over 24-48 hours (most protocols use 48 hours)
- Add maintenance (Holliday-Segar) to deficit replacement rate
- Do NOT exceed 1.5-2× maintenance rate (excessive fluid rates are associated with increased cerebral edema risk)
Step 2: Prepare 2 bags
| Bag | Composition |
|---|---|
| Bag A (no dextrose) | NS (0.9% NaCl) + 20 mEq/L KCl + 20 mEq/L KPhos (or 40 mEq/L KCl) |
| Bag B (with dextrose) | D10NS (10% dextrose in 0.9% NaCl) + 20 mEq/L KCl + 20 mEq/L KPhos |
Step 3: Adjust rates based on blood glucose
| Blood Glucose | Bag A Rate | Bag B Rate | Effective Dextrose |
|---|---|---|---|
| >300 mg/dL | 100% of total rate | 0% | 0% dextrose |
| 250-300 mg/dL | 75% | 25% | 2.5% dextrose |
| 200-250 mg/dL | 50% | 50% | 5% dextrose |
| 150-200 mg/dL | 25% | 75% | 7.5% dextrose |
| <150 mg/dL | 0% | 100% | 10% dextrose |
Goal: maintain blood glucose between 150-300 mg/dL during DKA treatment; glucose should decline by no more than 50-100 mg/dL per hour
5.4 Insulin Therapy
| Parameter | Details |
|---|---|
| When to start | 1-2 hours AFTER starting IV fluids (NOT at time of presentation); initial fluid resuscitation alone lowers glucose; starting insulin too early accelerates osmolality shifts |
| Preparation | Regular insulin 50 units in 50 mL NS (1 unit/mL) OR 50 units in 500 mL NS (0.1 unit/mL); prime tubing with insulin solution before connecting (insulin adsorbs to IV tubing) |
| Starting dose | 0.05-0.1 units/kg/hr continuous infusion; 0.05 units/kg/hr is increasingly preferred to avoid excessively rapid glucose decline |
| Do NOT give insulin bolus | Insulin boluses are contraindicated in pediatric DKA (associated with increased cerebral edema risk) |
| Titration | Target glucose decline of 50-100 mg/dL/hr; if glucose falling too fast, increase dextrose concentration (2-bag system) rather than decreasing insulin rate |
| Minimum insulin rate | 0.03-0.05 units/kg/hr; do NOT turn off insulin drip — add more dextrose instead (turning off insulin prolongs ketoacidosis) |
| Transition to subcutaneous | When ALL of the following are met: venous pH >7.30, bicarbonate >15 mEq/L, anion gap closed (<12), patient tolerating oral intake, beta-hydroxybutyrate <1 mmol/L; overlap IV and SC insulin by 30-60 minutes before discontinuing drip |
5.5 Cerebral Edema Monitoring and Management
Cerebral edema is the leading cause of death in children with DKA. Risk factors include younger age (<5 years), new-onset diabetes, severe DKA (pH <7.1), higher initial BUN, failure of Na to rise with treatment, and excessive fluid administration.8 9
Warning Signs (Modified GCS assessment q1h):
| Warning Sign | Description |
|---|---|
| Headache | New, worsening, or persistent headache during treatment |
| Altered mental status | Deterioration in GCS; inappropriate irritability or somnolence; failure to improve as expected |
| Vital sign changes | Bradycardia, hypertension (Cushing response); irregular respirations |
| Neurologic signs | Posturing (decorticate/decerebrate); pupillary asymmetry; cranial nerve palsies (especially CN III and VI); papilledema |
| Incontinence | New onset urinary incontinence in a previously continent child |
Emergency Treatment of Cerebral Edema:
| Priority | Intervention | Details |
|---|---|---|
| 1 | Reduce IV fluid rate | Reduce to minimum rate immediately |
| 2 | Elevate head of bed | 30 degrees; keep head midline |
| 3 | Mannitol | 0.5-1 g/kg IV over 15-20 minutes; may repeat in 30 minutes if no response; keep serum osmolality <320 mOsm/kg |
| 4 | Hypertonic saline (alternative or adjunct) | 3% NaCl: 2.5-5 mL/kg IV over 10-15 minutes; may be preferred if hypotensive (mannitol causes diuresis) |
| 5 | Intubation | If GCS ≤8 or respiratory failure; avoid hyperventilation (target PaCO2 35-40 mmHg); mild hyperventilation (PaCO2 30-35) only as temporizing measure for imminent herniation |
| 6 | CT head | Once patient is stabilized; assess for herniation, hemorrhage, or other structural cause |
| 7 | Neurosurgery consultation | For consideration of ICP monitoring or decompressive craniectomy in refractory cases |
5.6 Monitoring Schedule During DKA Treatment
| Parameter | Frequency |
|---|---|
| Point-of-care glucose | Every 1 hour |
| Neurologic status (GCS) | Every 1 hour |
| Vital signs | Every 1 hour (continuous telemetry) |
| BMP (Na, K, Cl, CO2, glucose, BUN, Cr) | Every 2-4 hours |
| VBG (pH, pCO2) | Every 2-4 hours |
| Beta-hydroxybutyrate | Every 2-4 hours |
| Calcium, magnesium, phosphorus | Every 4-6 hours |
| Strict intake and output | Continuous |
5.7 Corrected Sodium Calculation
Hyperglycemia causes dilutional hyponatremia by drawing water into the intravascular space. Corrected sodium should be calculated and trended during DKA treatment.
Corrected Na = Measured Na + 1.6 × [(glucose - 100) / 100]
- Corrected sodium should rise as glucose falls during treatment
- Failure of corrected Na to rise (or a falling corrected Na) suggests excessive free water administration and is a risk factor for cerebral edema8 9
6. Hypoglycemia in Children
6.1 Definition and Thresholds
| Age | Hypoglycemia Threshold | Critical Sample Threshold |
|---|---|---|
| Neonate (0-48 hours) | <40 mg/dL (guideline varies; some use <45) | Obtain critical sample before correction if glucose <50 |
| Neonate (>48 hours) | <50 mg/dL | Same |
| Infant/child | <60 mg/dL (symptomatic) or <50 mg/dL (any) | Obtain critical sample before correction when etiology unknown |
6.2 Treatment
| Scenario | Treatment | Notes |
|---|---|---|
| Neonate | D10W 2-4 mL/kg IV push, followed by D10W maintenance at 5-8 mg/kg/min glucose infusion rate | NEVER use D25W or D50W in neonates (hyperosmolar, risk of cerebral injury and phlebitis) |
| Infant/toddler | D25W 2-4 mL/kg IV push | D25W = 250 mg/mL dextrose |
| Older child/adolescent | D50W 1-2 mL/kg IV push (max 25 g) | D50W = 500 mg/mL dextrose |
| No IV access | Glucagon 0.03 mg/kg IM/SC (min 0.1 mg, max 1 mg) or 0.5 mg IM (<25 kg) / 1 mg IM (≥25 kg) | Onset 10-20 minutes; may cause nausea; less effective in glycogen-depleted states (malnutrition, hepatic disease) |
| Mild, alert, tolerating PO | Oral glucose: juice, glucose tablets, or glucose gel (15-30 g of rapid-acting carbohydrate) | Recheck glucose in 15 minutes |
Subcommittee on Febrile Seizures. “Febrile Seizures: Guideline for the Neurodiagnostic Evaluation of the Child with a Simple Febrile Seizure.” Pediatrics. 2011;127(2):389-394. DOI: 10.1542/peds.2010-3318 ↩︎ ↩︎
Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. “Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child with Simple Febrile Seizures.” Pediatrics. 2008;121(6):1281-1286. DOI: 10.1542/peds.2008-0939 ↩︎
Glauser T, Shinnar S, Gloss D, et al. “Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.” Epilepsy Curr. 2016;16(1):48-61. DOI: 10.5698/1535-7597-16.1.48 ↩︎ ↩︎
Kapur J, Elm J, Chamberlain JM, et al. “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus (ESETT).” N Engl J Med. 2019;381(22):2103-2113. DOI: 10.1056/NEJMoa1905795 ↩︎ ↩︎ ↩︎
Freedman SB, Vandermeer B, Milne A, et al. “Diagnosing Clinically Significant Dehydration in Children with Acute Gastroenteritis Using Noninvasive Methods: A Meta-Analysis.” J Pediatr. 2015;166(4):908-916.e6. DOI: 10.1016/j.jpeds.2014.12.029 ↩︎ ↩︎ ↩︎ ↩︎
World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers, 4th rev. Geneva: WHO; 2005. URL: https://www.who.int/publications/i/item/9241593180 ↩︎ ↩︎ ↩︎
Moritz ML, Ayus JC. “Prevention of Hospital-Acquired Hyponatremia: Do We Have the Answers?” Pediatrics. 2011;128(5):980-983. DOI: 10.1542/peds.2011-2015 ↩︎ ↩︎
Wolfsdorf JI, Glaser N, Agus M, et al. “ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic Ketoacidosis and the Hyperglycemic Hyperosmolar State.” Pediatr Diabetes. 2018;19(Suppl 27):155-177. DOI: 10.1111/pedi.12701 ↩︎ ↩︎ ↩︎ ↩︎
Glaser N, Barnett P, McCaslin I, et al. “Risk Factors for Cerebral Edema in Children with Diabetic Ketoacidosis.” N Engl J Med. 2001;344(4):264-269. DOI: 10.1056/NEJM200101253440404 ↩︎ ↩︎ ↩︎ ↩︎